These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32941646)

  • 1. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.
    Hodges JR; Phillips SM; Norell S; Nwosu C; Khan H; Luo L; Badawy SM; King A; Tanabe P; Treadwell M; Rojas Smith L; Calhoun C; Hankins JS; Porter J
    Blood Adv; 2020 Sep; 4(18):4463-4473. PubMed ID: 32941646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.
    Treadwell MJ; Du L; Bhasin N; Marsh AM; Wun T; Bender MA; Wong TE; Crook N; Chung JH; Norman S; Camilo N; Cavazos J; Nugent D
    Front Genet; 2022; 13():921432. PubMed ID: 36092883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
    Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
    JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
    Hankins JS; Shah N; DiMartino L; Brambilla D; Fernandez ME; Gibson RW; Gordeuk VR; Lottenberg R; Kutlar A; Melvin C; Simon J; Wun T; Treadwell M; Calhoun C; Baumann A; Potter MB; Klesges L; Bosworth H;
    JMIR Res Protoc; 2020 Jul; 9(7):e16319. PubMed ID: 32442144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
    Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
    BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication adherence among pediatric patients with sickle cell disease: a systematic review.
    Walsh KE; Cutrona SL; Kavanagh PL; Crosby LE; Malone C; Lobner K; Bundy DG
    Pediatrics; 2014 Dec; 134(6):1175-83. PubMed ID: 25404717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
    Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
    JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.
    Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385
    [No Abstract]   [Full Text] [Related]  

  • 10. When can cancer patient treatment nonadherence be considered intentional or unintentional? A scoping review.
    Wreyford L; Gururajan R; Zhou X
    PLoS One; 2023; 18(5):e0282180. PubMed ID: 37134109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease.
    Creary SE; Modi AC; Stanek JR; Chisolm DJ; O'Brien SH; Nwankwo C; Crosby LE
    J Pediatr Psychol; 2019 Nov; 44(10):1196-1204. PubMed ID: 31403687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease.
    Badawy SM; Thompson AA; Liem RI
    Pediatr Blood Cancer; 2016 May; 63(5):848-52. PubMed ID: 26844685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus.
    Daleboudt GM; Broadbent E; McQueen F; Kaptein AA
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):342-50. PubMed ID: 21120967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease.
    Fogarty H; Gaul A; Syed S; Aleksejenko N; Geoghegan R; Conroy H; Crampton E; Ngwenya N; Tuohy E; McMahon C
    Ir J Med Sci; 2022 Apr; 191(2):809-816. PubMed ID: 33745105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study to identify correlates of intentional versus unintentional nonadherence to analgesic treatment for cancer pain.
    Meghani SH; Bruner DW
    Pain Manag Nurs; 2013 Jun; 14(2):e22-30. PubMed ID: 23688368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
    Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI
    Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease.
    Pandey A; Raja R; Estepp JH; Ramkrishna D
    CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):748-757. PubMed ID: 37194405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma.
    Rees G; Leong O; Crowston JG; Lamoureux EL
    Ophthalmology; 2010 May; 117(5):903-8. PubMed ID: 20153902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beliefs about hydroxyurea in youth with sickle cell disease.
    Badawy SM; Thompson AA; Liem RI
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):142-148. PubMed ID: 29397333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.